WST · WEST PHARMACEUTICAL SERVICES INC

Back to holdings

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products.

Close · 3M

+24.20%

Held by 1 AI ETF

AIEQ0.050%

as of Sep 4

Signal performance

Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.

Buy signals4

Win rate50% (2/4)

Avg buy return-2.83%

AIEQnow 0.050% of fund8 signals

AIEQ · New entry · 1d

weight 0 → 0.050% (new)·stock up 3.2% in the 30 days before

Sep 1·entry $338.65·now $339.97Fresh

+0.39%

since Sep 1

AIEQ · Exit · 1d

weight 1.860% → 0 (exited)·stock down 6.6% in the 30 days before

Aug 2·entry $347.94·now $339.97

-2.29%

since Aug 2

AIEQ · Weight increase · 2d

weight 1.810% → 1.870% (+0.060 pp)·stock down 5.4% in the 30 days before

Jul 30·entry $339.59·now $339.97Fresh

+0.11%

since Jul 30

AIEQ · Weight decrease · 2d

weight 1.940% → 1.910% (-0.030 pp)·stock up 5.7% in the 30 days before

Jul 11·entry $359.70·now $339.97

-5.49%

since Jul 11

AIEQ · Weight increase · 2d

weight 0 → 2.000% (new)·stock up 17.2% in the 30 days before

Jul 3·entry $357.64·now $339.97Fresh

-4.94%

since Jul 3

AIEQ · New entry · 1d

weight 0 → 1.970% (new)·stock up 15.4% in the 30 days before

Jul 1·entry $365.00·now $339.97Fresh

-6.86%

since Jul 1

AIEQ · Exit · 1d

weight 0.360% → 0 (exited)·stock up 19.0% in the 30 days before

May 3·entry $300.18·now $339.97

+13.26%

since May 3

AIEQ · Weight decrease · 2d

weight 0.370% → 0.350% (-0.020 pp)·stock up 20.5% in the 30 days before

Apr 29·entry $295.36·now $339.97

+15.10%

since Apr 29

Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.

Buffett-style framework

Fails the frameworkas of Jul 12

The AI ETF AIEQ has recently shown interest in West Pharmaceutical Services, making a new entry and increasing its weight before a slight reduction from its peak. This activity contrasts with the value-investing framework's 'Fail' verdict, which is primarily driven by an inability to fully assess the company's financial health and the lack of a margin of safety at its current high valuation.

Circle of CompetenceThe business of providing specialized drug containment and delivery systems offers stable unit economics, allowing for reasonably predictable ten-year cash flow projections within the circle of competence.
Economic MoatWest Pharmaceutical Services benefits from high customer switching costs due to regulatory requirements and product integration, along with a strong reputation for quality in a highly regulated industry, creating a durable economic moat.
ManagementManagement's candor, capital allocation discipline, and skin in the game cannot be assessed with the provided financial summary.
Financial HealthCritical financial health criteria such as 10-year ROE trend, operating margin stability, debt manageability, and owner earnings consistency cannot be fully evaluated with the limited data provided, preventing a pass.
Margin of SafetyThe high valuation multiples (PER 46.06, EV/EBITDA 53.89) suggest the current price offers no defensible discount to a conservative estimate of intrinsic value, failing the margin of safety criterion.

West Pharmaceutical Services operates in a niche providing essential healthcare supplies, exhibiting predictable unit economics and a strong economic moat due to high switching costs and regulatory barriers. However, a comprehensive assessment of financial health and management quality is hampered by insufficient data. Crucially, the current market valuation indicates an absence of a margin of safety, leading to an overall 'Fail' within this value-investing framework.

Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.